ReviewVascular health and risk management2008
Beta-glucans in the treatment of diabetes and associated cardiovascular risks.
Review in Vascular health and risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 180 citations in OpenAlex.
- Effect of oat supplementation interventions on cardiovascular disease risk markers: a systematic review and meta-analysis of randomized controlled trials.European journal of nutrition · 2022Pooled it
- The effect of oat bran consumption on gestational diabetes: a randomized controlled clinical trial.BMC endocrine disorders · 2021Trial
- Trial
- Analysis of influencing factors of sleep quality in severe trauma patients without continuous sedation.Frontiers in medicine · 2025Article
- Knowledge mapping of trained immunity/innate immune memory: Insights from two decades of studies.Human vaccines & immunotherapeutics · 2024Review
- Harnessing Prebiotics to Improve Type 2 Diabetes Outcomes.Nutrients · 2024Review
- Therapeutic Potentials of Microalgae and Their Bioactive Compounds on Diabetes Mellitus.Marine drugs · 2023Review
- Utilization of dietary mixed-linkage β-glucans by the Firmicute Blautia producta.The Journal of biological chemistry · 2023Article
- Effects of Four Different Dietary Fibre Supplements on Weight Loss and Lipid and Glucose Serum Profiles during Energy Restriction in Patients with Traits of Metabolic Syndrome: A Comparative, Randomized, Placebo-Controlled Study.Foods (Basel, Switzerland) · 2023Article
- β-Glucan and Fatty Acid Based Mucoadhesive Carrier for Gastrointestinal Tract Specific Local and Sustained Drug Delivery.Biomolecules · 2023Article
- Exopolysaccharide from the yeast Papiliotrema terrestris PT22AV for skin wound healing.Journal of advanced research · 2023Article
- Impact of a high dietary fiber cereal meal intervention on body weight, adipose distribution, and cardiovascular risk among individuals with type 2 diabetes.Frontiers in endocrinology · 2023Article
- Review
- Effect of synbiotic bread containing lactic acid on blood lipids and apolipoproteins in patients with type 2 diabetes: A randomized controlled trial.Food science & nutrition · 2022Article
- Ameliorative and Antioxidative Potential ofAntioxidants (Basel, Switzerland) · 2022Article
- Trehalose Activates Hepatic and Myocardial Autophagy and Has Anti-Inflammatory Effects inLife (Basel, Switzerland) · 2022Article
- Recent Progress in Development of Dressings Used for Diabetic Wounds with Special Emphasis on Scaffolds.BioMed research international · 2022Review
- Article
- Biological Effects of β-Glucans on Osteoclastogenesis.Molecules (Basel, Switzerland) · 2021Review
- Recent Advances in Biopolymeric Composite Materials for Tissue Engineering and Regenerative Medicines: A Review.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is characterized by high blood glucose level with typical manifestations of thirst, polyuria, polydipsia, and weight loss. It is caused by defects in insulin-mediated signal pathways, resulting in decreased glucose transportation from blood into muscle and fat cells. The major risk is vascular injury leading to heart disease, which is accelerated by increased lipid levels and hypertension. Management of diabetes includes: control of blood glucose level and lipids; and reduction of hypertension. Dietary intake of beta-glucans has been shown to reduce all these risk factors to benefit the treatment of diabetes and associated complications. In addition, beta-glucans also promote wound healing and alleviate ischemic heart injury. However, the mechanisms behind the effect of beta-glucans on diabetes and associated complications need to be further studied using pure beta-glucan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.